Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 0.67 |
| ▸ | MAOB | P27338 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenethylamine SCHEMBL968 | 1.00 | — | — | |
| Phenethylamine SCHEMBL1331271 | 1.00 | — | — | |
| Phenethylamine SCHEMBL1330939 | 1.00 | — | — | |
| Phenethylamine SCHEMBL1332244 | 1.00 | — | — | |
| Phenethylamine SCHEMBL8384113 | 0.97 | HTR2A (0.94) | HTR2ALOXL2TAAR1CYP2A6SMN1; SMN2 | |
| Phenethylamine SCHEMBL20568335 | 0.97 | HTR2A (0.94) | HTR2ALOXL2TAAR1CYP2A6SMN1; SMN2 | |
| Phenethylamine SCHEMBL9650507 | 0.97 | HTR2A (0.94) | HTR2ALOXL2TAAR1CYP2A6SMN1; SMN2 | |
| Phenethylamine SCHEMBL245154 | 0.97 | HTR2A (0.94) | HTR2ALOXL2TAAR1CYP2A6SMN1; SMN2 | |
| Phenethylamine SCHEMBL837569 | 0.97 | HTR2A (0.94) | HTR2ALOXL2TAAR1CYP2A6SMN1; SMN2 | |
| Phenethylamine SCHEMBL5306641 | 0.97 | HTR2A (0.94) | HTR2ALOXL2TAAR1CYP2A6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11062794-B2 | Olfactory signature and odorant mixture having the same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-07-13 | — | — | US | disclosed |
| EP-3091970-B1 | LXR AGONISTS AND USES THEREOF | RGENIX INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10669296-B2 | LXR agonists and uses thereof | RGENIX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180253534-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-09-06 | — | — | US | disclosed |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | INSPIRNA, INC. | 2017-03-09 | — | — | US | disclosed |
| EP-3091970-A1 | LXR AGONISTS AND USES THEREOF | Rgenix, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015106164-A1 | LXR AGONISTS AND USES THEREOF | RGENIX, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2013035070-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-03-14 | — | — | WO | disclosed |
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7560586-B2 | Acid and ester compounds and methods of using the same | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| WO-2003082802-A1 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1318976-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2003-06-18 | — | — | EP | disclosed |
| US-20020137057-A1 | Rapid, quantitative method for the mass spectrometric analysis of nucleic acids for gene expression and genotyping | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2002-09-26 | — | — | US | disclosed |
| WO-2002024632-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002010186-A1 | A RAPID, QUANTITATIVE METHOD FOR THE MASS SPECTROMETRIC ANALYSIS OF NUCLEIC ACIDS FOR GENE EXPRESSION AND GENOTYPING | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-0900207-B1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5536853-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1996-07-16 | — | — | US | disclosed |
| WO-1995027729-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| US-3953458-A | HYPOTENSIVE AGENTS | MARION LABORATORIES, INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669296-B2 | LXR agonists and uses thereof | NR1H3, NR1H2, NR1H4 | HTR2A 1668/4885LOXL2 736/4885TAAR1 494/4885 |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | NR1H3, NR1H2, NR1H4 | HTR2A 1668/4885LOXL2 736/4885TAAR1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.